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Abstract 
A surface plasmon resonance-based solution affinity assay is described for 
measuring the Kd of binding of heparin/heparan sulfate-binding proteins with a variety 
ligands. The assay involves the passage of a pre-equilibrated solution of protein and 
ligand over a sensor chip onto which heparin has been immobilised. Heparin sensor 
chips prepared by four different methods, including biotin-streptavidin affinity 
capture and direct covalent attachment to the chip surface, were successfully used in 
the assay and gave similar Kd values. The assay is applicable to a wide variety of 
heparin/HS-binding proteins of diverse structure and function (e.g., FGF-1, FGF-2, 
VEGF, IL-8, MCP-2, ATIII, PF4) and to ligands of varying molecular weight and 
degree of sulfation (e.g., heparin, PI-88, sucrose octasulfate, naphthalene trisulfonate) 
and is thus well suited for the rapid screening of ligands in drug discovery 
applications.  
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Introduction 
Heparin and heparan sulfate (HS)
†
 are members of the glycosaminoglycan 
(GAG) family of linear, polyanionic polysaccharides composed of repeating 
disaccharide subunits of uronic acid-(1→4)-D-glucosamine 1-3. They share a common 
biosynthetic pathway in which numerous modifications are made to these subunits 
resulting in a large number of complex sequences 
4
. The uronic acid component can 
be either -D-glucuronic acid (GlcA) or its C-5 epimer, -L-iduronic acid (IdoA), 
which can also be sulfated at the 2-O position. The glucosamine may be either N-
acetylated or N-sulfated (or in rare cases, unsubstituted) and may contain further 
sulfation at the 6-O and 3-O positions.  
HS is ubiquitously expressed as a proteoglycan on the surface of most animal 
cells and as a component of extracellular matrices and basement membranes. HS 
interacts with a large range of proteins involved in many biological processes, for 
example, cell growth and development 
5
, tumour metastasis and angiogenesis 
6
, 
inflammation 
7
 and viral infection 
8
. The more highly sulfated heparin, which has been 
used clinically as an anticoagulant for decades and is thus widely available, is often 
used as a model compound for HS. The important role of HS/heparin in mediating 
                                                 
†
 Abbreviations: HS, heparan sulfate; GAG, glycosaminoglycan; SPR, surface 
plasmon resonance; FGF-1, fibroblast growth factor 1; FGF-2, fibroblast growth 
factor 2; VEGF, vascular endothelial growth factor; IL-8, interleukin 8; MCP-2, 
monocyte chemotactic protein 2; PF4, platelet factor 4; ATIII, antithrombin III; 
ADHZ, adipic acid dihydrazide; NHS, N-hydroxysuccinimide; EDC, N- (3-
dimethylaminopropyl)-N’-ethylcarbodiimide; LMWH, low molecular weight heparin; 
NTS, 1,3,6-naphthalenetrisulfonate; SOS, sucrose octasulfate. 
4 
these diverse biological functions has made these molecules the focus of much 
research 
9-11
. The potential for mimetics of heparin/HS in the treatment of diseases 
such as cancer and cardiovascular disease, has been recognized and is an area of much 
recent interest 
12-14
. The evaluation of binding specificities and affinities of potential 
ligands forms a major component of such drug discovery research.  
Surface plasmon resonance (SPR) spectroscopy is an established method for 
measuring biomolecular interactions and has been successfully used to study the 
binding affinities and kinetics of heparin-protein interactions 
15-20
. SPR-based binding 
experiments typically involve the immobilisation of one of the binding partners onto a 
sensor chip surface, followed by injection of the second molecule over the surface. 
The binding interaction between the two molecules results in a change in the intensity 
and angle of light reflected from the sensor chip surface, reported as a response 
increase, from which kinetic parameters can be derived. When studying heparin-
protein interactions by SPR, heparin is preferentially immobilised onto the sensor chip 
rather than the protein because this more closely mimics natural biological systems 
where HS is found at the cell surface as a proteoglycan and binds to target proteins as 
they flow past 
21,22
. In drug discovery applications where libraries of compounds are 
screened against a target protein, however, the immobilisation of the protein is usually 
required because it is impractical to immobilise each ligand separately, especially if 
the library is structurally diverse and requires multiple immobilisation chemistries. A 
drawback of this approach is the requirement of large amounts of available protein for 
immobilisation onto the sensor chip surface and is limited by the stability of the 
protein, particularly if harsh conditions are required to regenerate the sensor chip 
surface.  
5 
To overcome some of these limitations, an SPR-based solution affinity assay 
was developed in which neither the protein nor the ligand of interest are immobilised. 
Instead, immobilised heparin is used to measure binding kinetics in solution. The 
principle of this assay is that in a mixture of protein and ligand at equilibrium, 
immobilised heparin can distinguish between free protein and protein complexed with 
ligand when the ligand has bound in the heparin binding site. Thus, when a mixture of 
protein and ligand at equilibrium is injected across a heparin surface, free protein in 
the mixture binds to immobilised heparin resulting in a binding response. Quantitation 
of free protein in a series of mixtures containing varying concentrations of ligand 
enables calculation of the ligand binding affinity. The assay was used to measure the 
binding of various ligands, including the antiangiogenic drug candidate PI-88 as well 
as heparin and HS, to the heparin-binding, angiogenic growth factors FGF-1, FGF-2 
and VEGF 
23
. The assay was subsequently applied to the screening of various heparin-
mimetic compounds as potential antiangiogenic, anti-cancer agents 
24,25,12,26-28
.  
In this study, four different methods for the immobilisation of heparin onto 
sensor chips were investigated and the effects of the different sensor chips on the 
solution affinity assay were examined. In addition, the generality of this assay and its 
suitability for drug discovery screening was explored by analysing the binding of 
several heparin/HS-binding proteins of diverse structure and function with a number 
of known ligands of varying molecular weight and degree of sulfation.  
6 
Material and methods 
Materials 
Recombinant human FGF-1 (140 amino acid residue, N-terminally truncated 
form), recombinant human FGF-2 (146 amino acid residue, N-terminally truncated 
form), recombinant human VEGF (165 amino acid form), recombinant human IL-8 
(77 amino acid form), recombinant human MCP-2 and recombinant human PF4 were 
purchased from R&D Systems, Inc (Minneapolis, MN). Each of these protein 
preparations contained 50 µg of BSA per µg of growth factor. Human ATIII, heparin 
(from bovine lung or bovine intestinal mucosa, average mol. wt. ~ 12.5 kDa), adipic 
acid dihydrazide (ADHZ), 1,4-diaminobutane, N-hydroxysuccinimide (NHS), N- (3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDC), NaCNBH3, ethanolamine, low 
molecular weight heparin (LMWH, from porcine intestinal mucosa, average mol. wt. 
~ 3 kDa), heparin-albumin-biotin, albumin-biotin, heparin-biotin and 1,3,6-
naphthalenetrisulfonate (NTS) were purchased from Sigma. Sucrose octasulfate, 
potassium salt (SOS) was purchased from Toronto Research Chemicals (Toronto, 
Canada). PI-88 was supplied by Progen Pharmaceuticals (Brisbane, Australia). 
Streptavidin (SA), CM5, C1 and CM4 (B1) sensor chips and HBS-EP buffer (10 mM 
HEPES, pH 7.4, 150 mM NaCl, 3.0 mM EDTA and 0.005% (v/v) surfactant P20) 
were purchased from BIAcore AB (Uppsala, Sweden). Surface plasmon resonance 
(SPR) measurements were performed on a BIAcore 3000 (BIAcore) operated using 
the BIAcore Control Software.  
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Immobilisation of heparin-albumin-biotin onto streptavidin sensor chips  
The immobilisation of heparin-albumin-biotin onto streptavidin sensor chips 
has been described previously 
23
. A single injection of a 1 g/mL aqueous solution of 
heparin-albumin-biotin resulted in an increase in response of 60-200 response units 
(RU) in flow cells 2 and 4. Subsequent injections of heparin-albumin-biotin at 1-50 
g/mL did not result in further immobilisation. The remaining two flowcells were 
used as negative controls, with albumin-biotin immobilised in these using the above 
method. This resulted in a response increase of 360-730 RU. As the albumin-biotin 
does not bind to the proteins of interest here, the higher levels of immobilised 
albumin-biotin have no effect on the assay. 
Immobilisation of heparin-biotin onto streptavidin sensor chips 
 Biotinylated heparin was immobilised using the procedure described above. A 
single injection of 50 µL of 1 g/mL biotinylated heparin at a flow rate of 1 µL/min 
resulted in a response increase of 152 RU. The negative control flowcell remained 
unmodified. 
Immobilisation of heparin onto C1 and CM5 sensor chips via reductive amination 
with adipic acid dihydrazide 
Heparin was immobilised onto C1 and CM5 sensor chips using the method 
described by Satoh and Matsumoto 
29
 (see Scheme 1). Prior to immobilisation, the C1 
sensor chips were cleaned by consecutive injections of 10 L and 5 L of 0.1 M 
glycine-NaOH, 0.3% Triton-X100, followed by 5 L of HBS-EP buffer at 5 L/min. 
CM5 sensor chips were not treated. Flowcells were activated with a mixture of 200 
µL of 0.2 M EDC/0.05 M NHS at a flow rate of 5 L/min, and 200 µL of a near-
8 
saturated solution (approximately 100 mg/mL) of ADHZ in H2O was subsequently 
injected at the same flow rate. Heparin was immobilised onto the hydrazide group by 
injecting 150 µL of 100 mg/mL heparin in 2 M guanidine HCl, 7.5 mM sodium 
acetate buffer, pH 4, at 1 L/min, followed by injecting 80 µL of 1 mg/mL NaCNBH3 
at 2 L/min. For the C1 sensor chip, the above procedure was repeated to increase the 
heparin immobilisation level before injection of 200 µL of 1 M ethanolamine at 5 
µL/min to block any remaining activated sites. The flowcells were then washed with 
40 µL of 4 M NaCl followed by an HBS-EP buffer injection at 40 µL/min. On the C1 
and CM5 sensor chips, the negative control flowcells were left unmodified, since the 
level of non-specific binding of proteins to these flowcells was negligible and did not 
change following treatment of the flowcells with NHS/EDC and ethanolamine using 
the method described above. Following the heparin immobilisation procedure, the C1 
and CM5 sensor chips were undocked and soaked in HBS-EP buffer at 4 C for at 
least one week prior to use.  
Immobilisation of heparin onto CM4 sensor chips via reductive amination with 1,4-
diaminobutane 
In this immobilisation procedure, heparin was covalently attached by reductive 
amination to a surface modified by 1,4-diaminobutane 
30
 (see Scheme 1). The surface 
in flowcell 2 was activated by injection of 200 µL of a 0.05 M NHS and 0.2 M EDC 
mixture at 5 µL/min, resulting in a response increase of 795 RU. Following activation, 
200 µL of 1 M 1,4-diaminobutane was injected at 5 µL/min, and a response decrease 
of 682 RU was observed. A 200 µL solution of 1 M ethanolamine at 5 µL/min was 
injected, resulting in no further decrease in response. This suggests that this blocking 
9 
step may not be necessary because 1,4-diaminobutane is able to block all available 
activated sites.  
After undocking the sensor chip from the instrument, ~250 µL of 50 mg/mL 
heparin in water was applied to the sensor chip surface and the sensor chip left to 
stand overnight at room temperature. The solution was then replaced with ~250 µL of 
50 mg/mL heparin containing 2.5 mg/mL NaCNBH3 and left at room temperature for 
a further 20 hours. The surface was washed twice with ~500 µL of water, dried and 
then stored in HBS-EP buffer at 2-8 C for 1 week.  
Testing for heparin immobilisation  
To test the integrity of the heparin immobilised on these sensor chips, 25-200 
L of 1-3 nM FGF-1 in HBS-EP buffer was injected at 5-40 L/min. The sensor chip 
was deemed suitable for use in experiments if FGF-1 binding resulted in a response 
increase of >25 RU. Typically, a response increase of 50 RU or more was obtained in 
C1, CM5 or CM4 sensor chips. The surface was regenerated by injecting 40 L of 4 
M NaCl at 40 L/min, followed by injection of 40 L of HBS-EP buffer at 40 
L/min. 
Testing for mass transport 
The principle of the solution affinity assay method has been described 
previously 
23
. For successful application, this assay must be performed either under 
mass transport conditions, or the protein concentration used in the assay must be 10-
fold below its Kd with heparin, because only under these conditions are the binding 
responses linearly proportional to free protein concentration in the equilibrium 
mixture 
31
. Mass transport conditions are preferred because binding responses are 
10 
linearly proportional over a wider range of protein concentrations. Additionally, if the 
Kd is very low, use of a 10-fold lower protein concentration would give a very low 
response.  
To test whether or not mass transport conditions were established, standard 
curves were generated by injecting 25-200 L of standard protein solutions at varying 
concentrations in buffer (HBS-EP buffer for FGF-1, VEGF, MCP-2, IL-8 and ATIII, 
and HBS-EP buffer containing 0.3 M NaCl for FGF-2) at 5-40 L/min. Prior to 
injection, standard solutions were maintained at 4 C to maximize protein stability, 
and the surface binding experiments were performed at 25 C. The surface was 
regenerated by injection of 40 μL of 4 M NaCl at 40 μL/min, followed by injection of 
40 μL of buffer at 40 μL/min. Carry-over between injections was eliminated by 
including a DIPNEEDLE command between injections, and an EXTRACLEAN 
command after each injection. The standard curves obtained were linear and passed 
through the origin thus confirming that the assays were under mass transport 
conditions
32
 (see Fig. 1).  
Derivation of Kd values 
Kd values were derived as described previously 
23
. Briefly, 100-250 µL 
solutions were prepared containing 1.29-3 nM FGF-1, 0.5-3 nM FGF-2, 3 nM VEGF, 
45 nM IL-8, 4.4 nM MCP-2, 1 nM of ATIII and 5 nM PF4 and varying concentrations 
of the ligand in buffer on ice. For each assay mix, 25-200 L of solution was injected 
at 5-40 L/min and the relative response was measured. All surface binding 
experiments were performed at 25 C. Data analyses were carried out using the 
BIAevaluation version 3.0 software. The binding rates or responses for FGF-1, FGF-
11 
2, VEGF, IL-8, MCP-2, ATIII and PF4 were converted to free protein concentration 
using the method described by Karlsson 
23,31
.  
A stoichiometry of 1:1 was assumed for the protein:ligand complex formed in 
solution prior to injection,  
P + L    P·L (1) 
where P corresponds to the protein, L is the ligand and P·L is the protein:ligand 
complex. The equation for the equilibrium constant is  
LP
LP
K d  
(2) 
and the equation relating Kd to free protein concentration can be expressed as 
totaltotal
totaltotaldtotaltotald
total PL
PLKPLK
PP
42
)(
2
 
(3) 
where [P]total and [L]total represent the total concentrations of protein and ligand, 
respectively, in the injected solution 
23
.  
Under conditions of mass transport, standard curves relating the relative binding 
response to the injected protein concentration are linear 
32
. The relative binding 
response for each injection can, therefore, be converted to free protein concentration 
using the equation 
total
m
P
r
r
P  (4) 
where r is the relative binding response and rm is the maximal binding response (both 
responses were measured at 10 s before to the end of injection). A plot of [P] versus 
[L]total and fitting of equation (3) enables the determination of Kd. Initial binding rates 
can also be used instead of relative binding response to measure [P]. However, if the 
12 
initial binding rates are very fast then the traces may contain artifacts from buffer 
mixing 
31
. 
For the equilibrium in which a ligand binds cooperatively to the protein, 
P   +   nL         P Ln  
the equilibrium equation is 
 
n
n
d
LP
LP
K  
(5) 
The binding equation can be derived as above to give 
total
n
total
total
n
totaldtotal
n
totald
total PL
PLKPLK
PP
42
)(
2
 
(6) 
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Results and discussion 
Linear standard curves, which passed through the origin, relating relative 
responses to protein concentration in the absence of ligand, were obtained for each 
protein tested, indicating that all SPR measurements were performed under mass 
transport conditions 
23,31
.  
The use of a streptavidin-biotin-albumin-heparin sensor chip, prepared by 
passing a solution of commercially available heparin-albumin-biotin over a 
streptavidin chip, has been detailed previously for the solution affinity assay 
23
. In the 
present study the use of a streptavidin-biotin-heparin sensor chip (which contains no 
albumin), similarly prepared by passing a solution of commercially available heparin-
biotin over a streptavidin chip, is also described. In most previous SPR studies of 
heparin/HS-binding proteins, biotinylated heparin was similarly bound to streptavidin 
or avidin immobilised on the chip surface 
15,16,18,20
. However, the method of 
biotinylation of heparin can affect its binding to the protein 
21
 and many heparin-
binding proteins also interact non-specifically with avidin and streptavidin 
22
. The use 
of avidin can also be problematic because it is itself a heparin-binding protein 
33
. 
Furthermore, the streptavidin-biotin-heparin chip is not stable to the harsh 
regeneration conditions required for the removal of proteins that bind tightly 
22
. It was 
similarly found in this study that the streptavidin-biotin-(albumin)-heparin chips, in 
which the heparin is not covalently bound to the sensor chip, are not especially stable 
to harsh regeneration conditions. Additionally, the biotinylated species will dissociate 
from the streptavidin if the sensor chip is stored in HBS-EP buffer. Therefore, 
methods were sought to attach heparin covalently to the sensor chip, so that the sensor 
14 
chip can better withstand harsh regeneration conditions and can be stored in HBS-EP 
buffer for long periods of time without losing its binding capacity.  
Heparin has been covalently bound to a sensor chip via a heparin-albumin 
conjugate with immobilisation through the primary amino groups of the albumin 
22
. 
However, the covalent attachment of heparin directly onto a sensor chip via its 
reducing end should present the heparin in a manner that more closely resembles a 
proteoglycan 
21
. The methodology for this type of attachment has recently been 
reviewed 
34
, and the method of Satoh and Matsumoto 
35,29
 was successfully applied 
here (Scheme 1). Briefly, hydrazide groups were firstly introduced onto an 
(EDC/NHS)-activated carboxylated dextran matrix of a CM5 sensor chip with adipic 
acid dihydrazide. Heparin was then immobilised onto the hydrazide groups via 
reductive amination of its reducing end aldehyde group. The method was also 
successfully applied to C1 sensor chips which have a carboxylated surface similar to 
CM5 chips but lack the dextran matrix 
36
. Kamei and co-workers 
30
 used a strategy 
similar to that of Satoh and Matsumoto to immobilise heparin onto the 
carboxymethylated dextran surface of evanescent wave biosensor cuvettes, utilising 
amino groups (introduced using 1,4-diaminobutane) instead of hydrazide groups. This 
method was successfully adapted to preparing sensor chips using CM4 chips 
(previously known as B1 chips), which are similar to CM5 chips but with a lower 
degree of carboxylation 
36
 (Scheme 1). The lower density of negative charge 
associated with the CM4 chip facilitates the approach of heparin to the surface to react 
with the amino groups by minimising the charge-charge repulsion. In our experience, 
these two immobilisation methods, particularly the latter, provide reproducible and 
stable sensor chips that can be used continuously for up to 6 months. 
15 
The four sensor chips described above were used in Kd determinations for four 
known ligands (heparin, PI-88, SOS and NTS) 
23,37,18,38
 binding to the HS-binding 
growth factors FGF-1, FGF-2 and VEGF (Table 1). In this way the effects of using 
different heparin sensor chips on the solution affinity assay was examined. The 
ligands chosen are of diverse structure, molecular weight range [434 (NTS) to 
~12,500 (heparin)] and degree of sulfation. The affinity of the compounds for the 
growth factors ranged from low nM to high µM and the Kd values obtained by using 
the four different sensor chips gave similar results for each protein-ligand pair. It is 
noteworthy that measuring such a large range of Kd values is normally not possible 
using direct binding kinetics on the BIAcore.
§
 This suggests that the assay is robust 
and the method of heparin immobilisation has little impact on the measurement of Kd 
values. This can in part be explained by the fact that the function of the immobilised 
heparin is to bind to free protein in the equilibrium solution, and does not depend on 
the activity of the heparin on the sensor chip as some kinetic models require 
21
.   
To further demonstrate the generality of the solution affinity assay to HS-
binding proteins, four HS-binding proteins of diverse structure and function were 
selected for study. The proteins were interleukin 8 (IL-8), a pro-inflammatory CXC 
chemokine, platelet factor 4 (PF4), a CXC chemokine released by activated platelets, 
antithrombin III (ATIII), a coagulation cascade serpin, and monocyte chemotactic 
protein 2 (MCP-2), a CC chemokine which plays a role in the inflammatory response 
of blood monocytes. The Kd values of binding to the ligands heparin, LMWH and PI-
88 were determined and the results are presented in Table 2. The Kd values presented 
                                                 
§
 Typical range of Kd values is 200 nM to 200 pM. BIAapplications Handbook, 
version AB, 1998. 
16 
in Tables 1 and 2 range from µM to pM and compare reasonably well with previously 
published data determined by various methods (Table 3). The range of Kd values 
reported in the literature vary considerably, particularly for heparin and LMWH as 
ligands. The reported values depend on the method used to determine them, the ionic 
strength of the buffer, the source of the heparin or LMWH and the resultant variability 
in molecular weight and charge distribution. The results obtained via the solution 
affinity assay are generally within or close to the reported ranges, indicating the 
applicability of the assay for studying these types of interactions.  
Most of the commercial protein preparations used in this study contained a 
large excess of BSA (typically 50 µg of BSA per µg of protein). To ensure that the 
BSA had no effect on the assay, solutions of BSA in buffer were passed over the 
sensor chip surface. The responses observed were typically <5 RU, indicating that 
BSA did not bind significantly to the sensor chip surface and thus its presence does 
not adversely affect the assay. As a further check, the assay was used to measure the 
affinity of heparin to recombinant FGF-1 prepared in house containing no BSA. The 
Kd value obtained (1.3 ± 0.6 nM) is consistent with that obtained in the presence of 
BSA (2.4 ± 0.1 nM), confirming the benign nature of BSA in this assay. 
The solution affinity assay involves the mixing of protein, held at a constant 
concentration, with ligand at varying concentrations. After incubation, the mixture is 
injected over a surface onto which heparin has been immobilised. The binding of free 
protein to heparin is detected as an SPR response which decreases with increasing 
ligand concentration. It is important to note that this can only be observed when the 
interaction involves the heparin binding site, thus eliminating the possibility that non-
specific binding is being evaluated. Thus, the Kd values measured in this study apply 
17 
only to the interaction of ligand with the protein in its heparin-binding site. This is an 
important feature of this assay and makes it well suited to drug discovery where the 
main objective is the identification of ligands that can compete with heparin for 
binding to target proteins.  
During the assay it is assumed that exposure of the protein:ligand mixture to 
the heparin surface does not significantly affect the pre-established equilibrium 
between the protein and ligand. That is, only insignificant dissociation of the 
protein:ligand complex occurs during the time of contact of the mixture with the 
heparin surface 
39
. The flowcell in which heparin is immobilised has a volume of 20 
nL. At the flowrate of 5 L/min (the worst case scenario)
¶
 used during injection of the 
protein:ligand mixture, the contact time is calculated to be 0.24 s. If 1% dissociation 
of the complex is allowed in this time, the maximum permissible rate for dissociation 
can be calculated using the equation: 
tk
t
disseLPLP 0  
where [P L]t is the complex present at time t, and [P L]0 at time t=0. Allowing 1% 
dissociation in 0.24 s gives 
24.0
99.0 diss
k
e  
Thus, the maximum permissible dissociation rate, kdiss, is 0.042 s
-1
. The solution 
affinity assay does not allow measurement of the dissociation rate for a given 
protein:ligand complex. However, the kdiss reported for the interaction of FGF-1 with 
                                                 
¶
 Most assays are performed at flow rates of 20-40 µL/min which will further reduce 
the contact time. 
18 
heparin (0.016 s
-1 30
; 0.015 s
-1
 
22
), as well as a preliminary kinetic experiment on FGF-
1 binding to heparin in the current study (4.41 ± 0.02  10 
–3
 s
-1
, data not shown) 
indicated that the rate constant kdiss was well below the maximum permissible rate. On 
this evidence, the assumption that the pre-established equilibrium is not altered is 
valid.  
 
Although a stoichiometry of 1:1 was assumed for all protein:ligand 
interactions, it is well known that heparin/HS molecules contain many binding sites 
for a given protein that range from low to high affinity. Direct binding experiments of 
both FGF-1 and FGF-2 to immobilised heparin using SPR have previously been 
described, and relatively poor fits of the data to a simple 1:1 interaction model is 
evident 
30
. It has been suggested that the heterogeneity in FGF-1 binding to heparin 
may reflect the structural heterogeneity of the immobilised heparin. Alternatively, a 
single heparin molecule could contain multiple binding sites with varying degrees of 
affinity for FGF-1 and FGF-2 
30
. For FGF-1 and FGF-2 binding to heparin, both 
earlier 
18
 and more recent data 
40,41
 indicate that the stoichiometries may be far higher, 
up to 16:1 for FGF-1.  While this complex binding behaviour is apparent in direct 
binding assays, it cannot be observed in solution affinity assays. The Kd observed in 
the solution affinity assay is, therefore, a product of the individual binding equilibria 
between protein and heparin and in this case may be best described as an apparent Kd. 
Alternatively, the data can be expressed as an IC50 value. Like heparin/HS, the 
binding of protein to PI-88 (a complex mixture of sulfated oligosaccharides) is also a 
mixture of binding equilibria, and here also the observed Kd is a product of the 
binding of protein molecules to the individual components of the mixture. 
19 
IL-8 was highly unstable upon dilution into HBS-EP buffer.  Injection of 
freshly prepared 4.5 nM IL-8 resulted in a response increase until the injection time 
reached ~1.5 min, after which the binding response decreased rapidly.  Incubation of 
the diluted protein for up to 5 min on ice prior to injection resulted in complete loss of 
binding signal.  Addition of BSA or DTT or combinations of these to the diluted 
protein did not increase its stability.  Moreover, the concentrated protein sample was 
found to be stable.  Kd values for the ligands binding to IL-8 were, therefore, 
measured by preparing fresh dilutions of protein for each assay mixture.  The final 
concentration of IL-8 used in the assay mixes is relatively high at 45 nM compared 
with those used for the other proteins, however, at this concentration IL-8 is most 
likely still in its monomeric state as confirmed by the magnitude of the Kd values for 
heparin and LMWH. 49,56 
MCP-2 is dimeric,
60
 but stable upon dilution. When analysing the binding 
results for MCP-2, however, it was noticed that the fitted equation 3 deviated 
significantly from the data points.  Deviations from best fit were observed for all 
ligands except heparin. Inclusion of a Hill coefficient in the binding equation (i.e. 
equation 6) enabled a much better fit to the data.  The Hill coefficient refined to a 
value of ~1.5 for all the ligands except heparin (for which it was set to 1.0 by using 
equation 3), suggesting that there is more than one binding site for the ligand on the 
protein.  The results suggest, therefore, that there are two binding sites for the ligand 
on the protein dimer that bind the ligand cooperatively. 
The effect of buffer components, in particular NaCl, on the binding 
equilibrium was also considered. For all proteins except FGF-2 the binding affinities 
were measured in HBS-EP buffer at pH 7.4. This buffer is frequently used for binding 
20 
assays and is designed to mimic physiological conditions. For FGF-2 the NaCl 
concentration in the buffer was increased from 150 mM to 300 mM to reduce non-
specific binding to the sensor chip surface. The equilibrium considered here is only 
that of the interaction between protein and ligand. Interaction of components of the 
buffer with either the protein or ligand almost certainly exist as well, and these will 
have some effect on the protein:ligand equilibrium. In the case of FGF-2 where non-
specific binding of the protein is reduced by the addition of NaCl, the effect of Na
+
 
and Cl
-
 ions on the ligand binding equilibrium is likely to be greater.  
To measure the magnitude of this effect, several binding experiments with 
FGF-1 were conducted in HBS-EP buffer with NaCl concentration increased to 300 
mM (see Table 4). Of the three ligands measured (heparin, PI-88 and LMWH), the 
effect was greatest on PI-88. The Kd for this ligand binding to FGF-1 increased 35-
fold, while those for heparin and LMWH binding to FGF-1 increased by 8.5 and 15-
fold, respectively. A large effect on the Kd values due to NaCl is expected since both 
the ligand and protein are charged and their interaction has a significant ionic 
component.  Since PI-88 has a higher number of sulfate groups per monosaccharide 
compared to heparin and LMWH, the effect of NaCl on PI-88 binding is expected to 
be higher. Despite the increase in the Kd value for PI-88 binding to FGF-1, it is 15-
fold below that measured for FGF-2, indicating that PI-88 interacts preferentially with 
the former. Subsequently it was found that if the CM4 sensor chip is used for assaying 
FGF-2, the amount of salt in the running buffer can be significantly reduced to 180 
mM (see Table 4). This is possibly because the lower density of carboxyl groups on 
the CM4 chip causes less non-specific binding.   
Conclusions  
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In summary, we have reported a robust biochemical assay to determine the 
affinity of various ligands for heparin-binding proteins. Four different methods of 
heparin immobilisation onto the sensor chips were utilised and the dissociation 
constants for some known ligands were obtained. It was found that the Kd values 
obtained with different sensor chips were similar, however, sensor chips prepared by 
covalent attachment of heparin to the chip surface are preferred because they are more 
stable. Furthermore, the applicability of this assay method to a variety of other 
heparin-binding proteins was demonstrated. The fact that a single sensor chip can be 
used for measuring the affinity of ligands of various molecular weight and degree of 
sulfation for a variety of heparin-binding proteins, significantly reducing the sensor 
chip preparation time and reducing the protein consumption, makes this assay well 
suited to heparin/HS mimetic drug discovery applications.  
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Representative sensorgrams for each protein (FGF-1, FGF-2, VEGF, PF4, ATIII, 
MCP-2 and IL-8) and ligand (heparin, LMWH, PI-88, SOS and NTS) discussed in the 
text. Data from the negative control flow cells showing the level of non-specific 
binding are also provided.  
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Table 1. Kd values of selected compounds with FGF-1, FGF-2 and VEGF using different 
sensor chips 
 
Ligand Growth 
Factor 
SA chip 1
a
 SA chip 2
b
 CM5 or C1 chip
c
 CM4 (B1) chip
d
 
 FGF-1 4.2 ± 2.9 nM 5.8 ± 0.5 nM 5.1 ± 1.4 nM  1.7 ± 0.3 nM 
heparin FGF-2 5.3 ± 0.7 nM 1.6 ± 0.7 nM 7.5 ± 1.6 nM 5 ± 0.9 nM 
 VEGF 42.1 ± 4.5 nM 85.7 ± 11.9 nM 40.1 ± 8.4 nM 83 ± 8 nM 
 FGF-1 307 ± 128 pM 244 ± 26 pM 286 ± 108 pM 192 ± 25 pM 
PI-88 FGF-2 125 ± 12 nM 550 ± 90 nM 318 ± 32 nM 113 ± 3 nM 
 VEGF 2.8 ±1 nM 2.5 ± 0.6 nM 2.1 ± 0.5 nM 845 ± 285 pM 
 FGF-1 416 ± 94 nM 248 ± 8 nM 509 ± 124 nM 650 ± 217 nM 
SOS FGF-2 3.4 ± 0.4 µM 11.1 ± 2 µM 6.3 ± 0.9 µM 2.6 ± 0.2 µM 
 VEGF 137 ± 17 µM 154 ± 15 µM n.d. 57 ± 14 µM 
 FGF-1 n.d. 770 ± 50 µM 765 ± 334 µM 470 ± 139 µM 
NTS FGF-2 n.d. 230 ± 70 µM 193 ± 16 µM 150 ± 40 µM 
 VEGF n.d. 175 ± 12 µM 196 ± 34 µM 130 ± 13 µM 
a
 via heparin-albumin-biotin 
b
 via heparin-biotin 
c
 via ADHZ 
d
 via 1,4-diaminobutane 
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Table 2. Kd values of heparin, LMWH and PI-88 with IL-8, MCP-2, PF4 and ATIII 
 
Ligand MCP-2 IL-8 PF4 ATIII 
heparin 80 ± 4 nM 350 ± 40 nM 160 ± 30 pM 21.5 ± 1.0 nM 
LMWH 6.5 ± 1.8 µM 8.5 ± 0.6 µM 7.4 ± 0.8 nM 163 ± 10 nM 
PI-88 460 ± 40 nM 30 ± 4 µM 16.0 ± 1.9 nM 35.9 ± 2.0 µM 
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Table 3. Literature Kd values determined by various techniques for ligand and protein 
combinations used in this study.   
 
Ligand FGF-1 FGF-2 VEGF IL-8 PF4 ATIII 
Heparin 505 nM
42
  
~1 nM
43
   
5.0 nM
44
 
180 nM
30
 
7.9 nM
45
  
2.2 nM
46
   
~1 nM
43
    
71 nM
30
    
23 nM
47
 
157 nM
48
 
165 nM
47
 
37 M
49
 4.4 nM 
50
 
20 nM 51 
30 nM
52
 
 
48.8 nM
53
 
11 nM
46
 
57.4 nM
54
 
LMWH 461 nM
42
  
91 nM
46
 
470 nM
55
 
2.0 nM
46
 
 597 nM
56
 
5.5 M
57
 
27 nM
57
 16 nM
46
  
100 nM
54
 
PI-88  10.3 nM
45
     
SOS 3.4 M
42
 280 n M
58
 
170 M
59
 
    
NTS 50 M
37
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Table 4. Effects of NaCl in the running buffer on Kd values for FGF-1 and FGF-2 with selected 
compounds  
 
Ligand Kd FGF-1 
(150 mM NaCl) 
Kd FGF-1 
(300 mM NaCl) 
Kd FGF-2 
(180 mM NaCl) 
Kd FGF-2 
(300 mM NaCl) 
Heparin 2.4 ± 0.1 nM 20.4 ± 1.8 nM 160 ± 60 pM 5.0 ± 0.2 nM 
LMWH 17.3 ± 1.6 nM 260 ± 15 nM n.d. 84.1 ± 2.2 nM 
PI-88 237 ± 11 pM 8.4 ± 0.8 nM 4.5 ± 0.7 nM 130 ± 3 nM 
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Captions for Figures and Scheme 
Fig. 1. Representative protein standard curve determined for FGF-2. (a) SPR 
sensorgrams demonstrating the change in binding response (in RU) upon injection of 
varying concentrations of FGF-2 from 0-3 nM in HBS-EP running buffer containing 
0.3 M NaCl over a heparin surface. (b) Protein standard curve constructed by plotting 
the observed binding response against the protein concentration. 
Fig. 2. Representative Kd measurement of heparin binding to FGF-2. (a) SPR 
sensorgrams showing the change in binding response (in RU) upon injection of 3 nM 
FGF-2 mixed with varying concentrations of heparin from 0-100 nM in HBS-EP 
running buffer containing 0.3 M NaCl over a heparin surface. (b) Binding curve 
constructed by plotting free FGF-2 concentration against varying concentrations of 
heparin. Values for free FGF-2 concentration were calculated as described in 
Materials and Methods. 
Scheme 1. Immobilisation of heparin by reductive amination onto derivatised 
carboxylated sensor chips (CM5, C1 or CM4). Path a: via adipic acid dihydrazide 
(ADHZ), Path b: via 1,4-diaminobutane. 
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